General
Preferred name
FINGOLIMOD
Synonyms
FTY-720 ()
Fingolimod (FTY720) HCl ()
FTY720 HCl ()
FTY-720A ()
FTY 720 ()
FTY720 (Fingolimod) ()
Gilenya ()
FINGOLIMOD HYDROCHLORIDE ()
GSK618334 ()
Fingolimod (hydrochloride) ()
FTY720 free base ()
FTY720 ()
Fingolimod Hydrochloride,FTY720 ()
FTY-720A, FTY-720 ()
Fingolimod ()
Fingolimod hcl ()
FTY-720 HYDROCHLORIDE ()
FTY720 HYDROCHLORIDE ()
Fingolimod hydrochlorid ()
Fingolimod (as hydrochloride) ()
Fingolimod accord ()
Fingolimod mylan ()
Gilenia ()
Tascenso ()
Tascenso odt ()
FINGOLIMOD LAURYL SULFATE ()
Fingolimod-d4 ()
P&D ID
PD003633
CAS
162359-56-0
162359-55-9
1346747-38-3
Tags
available
drug
prodrug
Approved by
EMA
FDA
First approval
2021
2010
Drug indication
Relapsing-remitting multiple sclerosis
Nasopharyngeal carcinoma
Drug abuse
chronic progressive multiple sclerosis
Multiple sclerosis
Primary progressive multiple sclerosis
Drug Status
approved
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Fingolimod was the first approved oral therapy for multiple sclerosis.
Fingolimod FTY720) is the prodrug of a S1P receptor agonist . When fingolimod binds to S1P1R the complex is internalised and then degraded, so the drug acts as an indirect functional antagonist by preventing intracellular signalling. It acts as a lymphocyte migration inhibitor, promoting lymphocyte retention in lymphoid tissues, whilst preserving lymphocyte function . Clinical efficacy results from modulation of S1P1 receptors. Adverse effects are thought to be caused by fingolimod's off-target effects on other S1P receptor subtypes.
Selective S1P1R agonists are being developed and investigated for immunomodulatory/immunosuppresant potential.
COVID-19: Fingolimod has been evaluated in a small study of patients with moderate to severe COVID-19 (n=19), with mixed results . Three days of treatment (in addition to standard interventions) did not reduce intubation or mortality rates, compared to placebo controls (n= 21), but it did signficantly reduce the re-admission rate. (GtoPdb)
Fingolimod FTY720) is the prodrug of a S1P receptor agonist . When fingolimod binds to S1P1R the complex is internalised and then degraded, so the drug acts as an indirect functional antagonist by preventing intracellular signalling. It acts as a lymphocyte migration inhibitor, promoting lymphocyte retention in lymphoid tissues, whilst preserving lymphocyte function . Clinical efficacy results from modulation of S1P1 receptors. Adverse effects are thought to be caused by fingolimod's off-target effects on other S1P receptor subtypes.
Selective S1P1R agonists are being developed and investigated for immunomodulatory/immunosuppresant potential.
COVID-19: Fingolimod has been evaluated in a small study of patients with moderate to severe COVID-19 (n=19), with mixed results . Three days of treatment (in addition to standard interventions) did not reduce intubation or mortality rates, compared to placebo controls (n= 21), but it did signficantly reduce the re-admission rate. (GtoPdb)
DESCRIPTION
Fingolimod was the first approved oral therapy for multiple sclerosis.
Fingolimod FTY720) is the prodrug of a SIP receptor agonist . When fingolimod binds to SIP1 the complex is internalised and then degraded, so the drug acts as an indirect functional antagonist by preventing intracellular signalling. It acts as a lymphocyte migration inhibitor, promoting lymphocyte retention in lymphoid tissues, whilst preserving lymphocyte function . Clinical efficacy results from modulation of subtype 1 S1P (S1P1) receptors. Adverse effects are thought to be caused by fingolimod's off-target effects on othe SIP receptor subtypes.
Selective SIP1 receptor agonists are being developed and investigated for immunomodulatory/immunosuppresant potential.
Fingolimod FTY720) is the prodrug of a SIP receptor agonist . When fingolimod binds to SIP1 the complex is internalised and then degraded, so the drug acts as an indirect functional antagonist by preventing intracellular signalling. It acts as a lymphocyte migration inhibitor, promoting lymphocyte retention in lymphoid tissues, whilst preserving lymphocyte function . Clinical efficacy results from modulation of subtype 1 S1P (S1P1) receptors. Adverse effects are thought to be caused by fingolimod's off-target effects on othe SIP receptor subtypes.
Selective SIP1 receptor agonists are being developed and investigated for immunomodulatory/immunosuppresant potential.
ABSORPTION
The Tmax of fingolimod is 12-16 hours. ; Bioavailability: 93%
TOXICITY
Bradyarrhythmia and Atrioventricular Blocks; Risk of infections; Macular Edema; Respiratory Effects; Hepatic Effects ; Fetal Risk; Blood Pressure Effects; Immune System Effects Following Fingolimod Discontinuation
METABOLISM
3 main pathways: ; -reversible stereoselective phosphorylation to the pharmacologically active (S)-enantiomer of fingolimod-phosphate.; -oxidative biotransformation mainly via the cytochrome P450 4F2 isoenzyme and subsequent fatty acid-like degradation to inactive metabolites.; -by formation of pharmacologically inactive non-polar ceramide analogs of fingolimod.
PHARMACODYNAMICS
Fingolimod causes a transient reduction in heart rate and AV conduction at treatment initiation.; Potential to prolong the QT interval.; Effects on immune cell numbers in the blood- decreased lymphocyte counts.; Mild decrease in the neutrophil count- about 80% of original pre-therapy count.; Compared to placebo, antigen-specific IgM titers were decreased by 91% and 25% in response to KLH and PPV, respectively.; IgG titers were decreased by 45% and 50%, in response to KLH and PPV.; The capacity to mount a skin delayed-type hypersensitivity reaction to Candida and tetanus toxoid was decreased by approximately 30% in subjects on fingolimod 0.5 mg daily, compared to placebo. Immunologic responses were further decreased with fingolimod 1.25 mg (a dose higher than recommended for MS).; Single fingolimod doses â¥5 mg (10-fold the recommended dose) are associated with a dose-dependent increase in airway resistance.
PRICE
29
PRICE
29
DESCRIPTION
Fingolimod (FTY720) hydrochloride is a sphingosine 1-phosphate (S1P) antagonist with IC50 of 0.033 nM in K562 and NK cells. Fingolimod hydrochloride is also a pak1 activator and immunosuppressant[1][2][3][4].
DESCRIPTION
inhibitor of sphingosine 1-phosphate receptor
(Informer Set)
DESCRIPTION
Fingolimod (FTY-720A) is an antagonist of sphingosine 1-phosphate (S1P) (IC50 of 0.033 nM in K562 and NK cells).
(TargetMol Bioactive Compound Library)
DESCRIPTION
High affinity and selective CB1 antagonist
(Tocris Bioactive Compound Library)
DESCRIPTION
Fingolimod hydrochloride (FTY720) , a novel immune modulator, is a sphingosine 1-phosphate (S1P) antagonist (IC50: 0.033 nM in K562 and NK cells).
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
14
Organisms
1
Compound Sets
29
Axon Medchem Screening Library
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2023/24
Concise Guide to Pharmacology 2025/26
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP Approved Drugs
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
EUbOPEN Chemogenomics Library
Guide to Pharmacology
Informer Set
LSP-MoA library (Laboratory of Systems Pharmacology)
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
ReFrame library
Selleckchem Bioactive Compound Library
Tocris Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
195
Molecular Weight
307.25
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
12
Ring Count
1
Aromatic Ring Count
1
cLogP
3.2
TPSA
66.48
Fraction CSP3
0.68
Chiral centers
0.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
S1PR1
S1PR1, S1PR5
S1P agonist
LPL Receptor
PAK
LPL
S1P
Trpm7
Compound status
FDA
Pathway
Cytoskeletal Signaling
GPCR/G protein
Membrane Transporter/Ion Channel
Cell Cycle/DNA Damage
cytoskeleton
Primary Target
Sphingosine-1-Phosphate Receptors
MOA
S1P Receptor
Agonist
immunosuppressant, sphingosine 1-phosphate receptor agonist
Indication
multiple sclerosis
Therapeutic Indication
Multiple Sclerosis
Therapeutic Class
CNS & PNS
Recommended Cell Concentration
100 nM
Source data

